22nd Century Group to Present at the Rodman & Renshaw Global Investment Conference

Source from:  Business Wire 09/09/2011

22nd Century Group, Inc. (OTCBB: XXII), a company focused on smoking cessation and tobacco harm reduction products, announced today that it will present at the Rodman & Renshaw Annual Global Investment Conference to be held September 11-13, 2011 at the Waldorf Astoria in New York City. Joseph Pandolfino, founder and CEO, will deliver the company's corporate presentation on Monday, September 12th, at 1:30 PM Eastern time. Mr. Pandolfino will provide an update on the company's business, including its Phase II-B smoking-cessation clinical trial currently in progress. X-22, a prescription smoking cessation aid in development, consists of a kit of very low nicotine (VLN) cigarettes made from 22nd Century's proprietary tobacco. X-22 cigarettes contain 97% less nicotine than Marlboro® Gold, the U.S. cigarette market leader, formerly known as Marlboro Lights®. In the Phase II-B protocol, subjects are assigned to smoke X-22 (or active control cigarettes) during a 6-week treatment period to facilitate the goal of quitting by the end of 6 weeks. About 22nd Century Group, Inc. Founded in 1998, 22nd Century Limited, LLC (22nd Century) is a plant biotechnology company whose proprietary technology allows for the level of nicotine (and other nicotinic alkaloids) in the tobacco plant to be decreased or increased through genetic engineering and breeding. 22nd Century owns or is the exclusive worldwide licensee of 98 issued patents in 79 countries where at least 75% of the world's smokers reside. 22nd Century is committed to developing and commercializing (i) the world's most effective and acceptable smoking cessation aid and (ii) for those smokers who refuse to quit smoking, consumer-acceptable modified risk tobacco products that reduce exposure to smoke toxins, as compared to conventional cigarettes. Through a merger on January 25, 2011, 22nd Century became a wholly-owned subsidiary of 22nd Century Group, Inc. On August 8, 2011, the company announced that 22nd Century enrolled the first patients in its Phase II-B clinical trial for X-22. For additional information, please visit: www.xxiicentury.com. Enditem